文献速递冠心病心律失常

EXCEL试验:合并慢性肾脏病的左主干患者PCI与CABG血运重建比较

Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

基于EXCEL随机试验,按基线肾功能分析左主干低至中等解剖复杂度患者。CKD定义为eGFR<60 ml/min/1.73 m2,共361/1869例(19.3%)存在CKD。CKD患者3年主要复合终点(死亡、心梗或卒中)发生率更高(20.8% vs 13.5%;HR 1.60;95%CI 1.22-2.09;p=0.0005)。PCI与CABG在CKD和非CKD患者3年主要复合终点上均无显著差异。

要点

  • CKD患者左主干血运重建后3年死亡、心梗或卒中风险显著高于非CKD患者。
  • 30天内急性肾衰竭在CKD患者中更常见(5.0% vs 0.8%),且与3年不良事件强相关。
  • PCI较CABG显著降低急性肾衰竭发生率,CKD与非CKD患者中趋势一致。

核心结论

  • 合并CKD的左主干患者血运重建后急性肾衰竭发生率和事件-free生存率均更差。
  • PCI较CABG急性肾衰竭发生率更低。
  • CKD与非CKD患者中,PCI与CABG在3年死亡、卒中或心梗方面无显著差异。

研究设计与样本

  • EXCEL为多中心随机试验,比较PCI与CABG治疗左主干低至中等解剖复杂度患者。
  • CKD定义为eGFR<60 ml/min/1.73 m2(CKD-EPI公式),1869例随机患者中361例(19.3%)有基线eGFR并存在CKD。
  • 急性肾衰竭定义为血清肌酐较基线升高≥5.0 mg/dl或新需要透析。
  • 主要复合终点为3年随访时死亡、心肌梗死或卒中的复合终点。

主要发现

  • CKD患者3年主要复合终点发生率20.8%,非CKD患者13.5%(HR 1.60;95%CI 1.22-2.09;p=0.0005)。
  • 30天内急性肾衰竭在CKD患者中发生率5.0%,非CKD患者0.8%(p<0.0001)。
  • 发生急性肾衰竭者3年死亡、卒中或心梗风险50.7%,未发生者14.4%(HR 4.59;95%CI 2.73-7.73;p<0.0001)。
  • CKD患者中急性肾衰竭PCI后2.3%、CABG后7.7%(HR 0.28;95%CI 0.09-0.87);非CKD患者中PCI后0.3%、CABG后1.3%(HR 0.20;95%CI 0.04-0.90;交互p=0.71)。
  • CKD患者主要复合终点PCI后23.4%、CABG后18.1%(HR 1.25;95%CI 0.79-1.98);非CKD患者PCI后13.4%、CABG后13.5%(HR 0.97;95%CI 0.73-1.27;交互p=0.38)。

临床怎么用

  • 对合并CKD的左主干患者,PCI与CABG均可作为血运重建选项,3年硬终点无显著差异。
  • 选择血运重建方式时应权衡急性肾衰竭风险,PCI可能降低急性肾衰竭发生率。
  • 围术期需重视急性肾衰竭的预防与监测,因其与后续死亡、卒中或心梗风险强相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal revascularization strategy for patients with left main coronary artery disease (LMCAD) and chronic kidney disease (CKD) remains unclear. OBJECTIVES: This study investigated the comparative effectiveness of percutaneous coronary intervention (PCI) versus coronary artery bypass graft (CABG) surgery in patients with LMCAD and low or intermediate anatomical complexity according to baseline renal function from the multicenter randomized EXCEL (Evaluation of XIENCE Versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization) trial. METHODS: CKD was defined as an estimated glomerular filtration rate <60 ml/min/1.73 m2 using the CKD Epidemiology Collaboration equation. Acute renal failure (ARF) was defined as a serum creatinine increase ≥5.0 mg/dl from baseline or a new requirement for dialysis. The primary composite endpoint was the composite of death, myocardial infarction (MI), or stroke at 3-year follow-up. RESULTS: CKD was present in 361 of 1,869 randomized patients (19.3%) in whom baseline estimated glomerular filtration rate was available. Patients with CKD had higher 3-year rates of the primary endpoint compared with those without CKD (20.8% vs. 13.5%; hazard ratio [HR]: 1.60; 95% confidence interval [CI]: 1.22 to 2.09; p = 0.0005). ARF within 30 days occurred more commonly in patients with compared with those without CKD (5.0% vs. 0.8%; p < 0.0001), and was strongly associated with the 3-year risk of death, stroke, or MI (50.7% vs. 14.4%; HR: 4.59; 95% CI: 2.73 to 7.73; p < 0.0001). ARF occurred less commonly after revascularization with PCI compared with CABG both in patients with CKD (2.3% vs. 7.7%; HR: 0.28; 95% CI: 0.09 to 0.87) and in those without CKD (0.3% vs. 1.3%; HR: 0.20; 95% CI: 0.04 to 0.90; pinteraction = 0.71). There were no significant differences in the rates of the primary composite endpoint after PCI and CABG in patients with CKD (23.4% vs. 18.1%; HR: 1.25; 95% CI: 0.79 to 1.98) and without CKD (13.4% vs. 13.5%; HR: 0.97; 95% CI: 0.73 to 1.27; pinteraction = 0.38). CONCLUSIONS: Patients with CKD undergoing revascularization for LMCAD in the EXCEL trial had increased rates of ARF and reduced event-free survival. ARF occurred less frequently after PCI compared with CABG. There were no significant differences between PCI and CABG in terms of death, stroke, or MI at 3 years in patients with and without CKD. (EXCEL Clinical Trial [EXCEL]; NCT01205776).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Giustino G, Mehran R, Serruys PW, et al. Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial. J Am Coll Cardiol. 2018. PMID: 30092952. doi:10.1016/j.jacc.2018.05.057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。